Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes

Hinuma, Shuji; Onda, Haruo; Naruo, Ken‐ichi; Ichimori, Yuzo; Koyama, Masaru; Tsukamoto, Kikuo

doi:10.1016/0006-291x(82)91729-6

Cited by 42 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PBM at a concentration of 1 × 106/ml were cultured for 4 days in complete medium containing 1 U / m l recombinant IL-2 for preparation of L A K cells. The recombinant IL-2 was prepared at Takeda Pharmaceutical Co. (Osaka, Japan) and had a specific activity of 3.5 x l 0 4 U / m l as assayed on IL-2-dependent murine NKC3 cells [12]. The specific activity of recombinant IL-2 per unit was almost 300 times higher than that used in other studies.…”

Section: Methodsmentioning

confidence: 99%

Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients

Nakamura

Arinaga

Akiyoshi

1989

Cancer Immunol Immunother

View full text Add to dashboard Cite

The effect of mitomycin C administration on the generation of cytotoxic cells, induced by in vitro activation of peripheral blood mononuclear cells (PBM) with interleukin-2, was studied in patients with various carcinomas. The ability of PBM to generate lymphokine-activated killer (LAK) cell activity against Raji cell targets was significantly augmented 5 and 7 days after a single intravenous dose of 12 mg/m2 mitomycin C, when compared to that of PBM obtained before mitomycin C injection. Further, LAK cell activity against autologous tumor cells was also significantly increased after the drug administration. The distribution of lymphocyte subsets exhibited a significant increase in the percentage of CD3+ cells after injection, with the elevation of the CD4/CD8 ratio. Furthermore, the proportion of the CD4+ Leu8+ subpopulation, which identifies inducers of suppression, was significantly reduced. Thus, the decrease in the proportion of suppressor-inducer subsets of PBM might be at least partially, responsible for the augmented generation of LAK cells after mitomycin C administration.

show abstract

Section: Methodsmentioning

confidence: 99%

Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients

Nakamura

Arinaga

Akiyoshi

1989

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…Recombinant IL-2 (rIL-2) and rlFNa were supplied by Takeda Pharmaceuticals, Osaka, Japan. rIL-2 had a specific activity of 3.5 x 104 U/mg protein as assayed on IL-2-dependent murine NKC3 cells [12]. rIFNy and natural (n) TNF~ were supplied by Shionogi Pharmaceuticals, Osaka, Japan, and Mochida Pharmaceuticals, Tokyo, Japan, respectively.…”

Section: Methodsmentioning

confidence: 99%

Interferon γ but not tumor necrosis factor α decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells

Tomita

Watanabe

Kobayashi

et al. 1992

Cancer Immunol Immunother

View full text Add to dashboard Cite

Human renal cell cancer (RCC) cell lines, ACHN and KRC/Y, with or without exposure to cytokines, were examined for their susceptibility to lymphokine-activated killer (LAK) cells. Flow-cytometric analysis demonstrated constitutional expression of class I antigen on both cell lines, which was enhanced by interferon alpha (IFN alpha), IFN gamma and tumor necrosis factor alpha (TNF alpha). A 4-h 51Cr-release cytotoxicity assay demonstrated that pretreatment of both cell lines with IFN gamma or IFN alpha, but not with TNF alpha, decreased their susceptibility to LAK cells. IFN gamma also decreased susceptibility to natural killer cells in a 16-h 51Cr-release cytotoxicity assay. IFN gamma treatment decreased the susceptibility of ACHN cells in a dose-dependent manner. "Cold"-target competition assay clearly showed that IFN gamma- but not TNF alpha-pretreated cells compete less effectively than do untreated target cells. Pretreatment with IFN gamma, however, increased expression of intercellular adhesion molecule-1 (ICAM-1) to a degree comparable to that with TNF alpha. Northern blot analyses using a 520-base-pair ICAM-1 cDNA as a probe demonstrated that more 3.3-kb mRNA is expressed in IFN gamma- and TNF alpha-pretreated cells. These results suggest that IFN gamma-treated RCC cell lines may reduce their ability to be recognized by LAK cells, and that IFN-induced protection of RCC cell lines against LAK cells may depend upon a mechanism independent of the expression of class I antigens or ICAM-1 on tumor cells.

show abstract

“…On the other hand, the finding that IL2 does not bind on a lectin column (3) would seem to indicate that the protein is unglycosylated. Recently, IL2-mRNA isolated from mouse (15), primate (16), human tonsilar (17) and peripheral blood lymphocytes (18) has been translated in Xenopus laevis oocytes, while IL2-mRNA, isolated from a human T-cell line was efficiently translated in a reticulocyte lysate (11). Monoclonal antibodies binding human IL2 (19,20) and monoclonal antibodies specific for the human IL2 membrane receptor (21) have been prepared.…”

Section: Introductionmentioning

confidence: 99%

Molecular cloning of human interleukin 2 cDNA and its expression inE. coli

et al. 1983

View full text Add to dashboard Cite

show abstract

Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes

Cited by 42 publications

References 20 publications

Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients

Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients

Interferon γ but not tumor necrosis factor α decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells

Molecular cloning of human interleukin 2 cDNA and its expression inE. coli

Contact Info

Product

Resources

About